Better Quality of Life for People Living with Diabetes Through Innovative Artificial Intelligence Applications: Launch of EU Research Project MELISSA
Diabetes is on the rise worldwide and an increasing number of people with diabetes requires insulin therapy, a highly complex form of treatment that greatly impacts on the daily lives of those affected. The newly-launched EU research project MELISSA strives for every person with insulin-treated diabetes to receive tailored treatment and care according to their individual needs, resulting in a better quality of life.
MELISSA will develop new Artificial Intelligence (AI)-based digital diabetes management solutions which are supposed to become a gamechanger in the treatment of diabetes.
To meet the objectives, the consortium brings together partners active in the fields of diabetes (People with Diabetes and Healthcare Professionals), diabetes technology, AI, behavioural sciences, ethics in AI, regulatory affairs, innovation management, healthcare economics and clinical trials to further co-create, clinically develop, optimise, and clinically validate an AI-based solution for more effective and cost-efficient diabetes management through personalised treatment and care.
EURICE is member of the 12-partner strong consortium and takes the lead in the overall project management of the project and pro-actively drives the communication, dissemination and innovation management strategies for this pioneering research endeavour.
“MELISSA is an exciting continuation of our growing portfolio of projects addressing the burden of diabetes for people in Europe and worldwide. We are excited to be part of this ambitious project and look forward to the discussions around the business case for the MELISSA results”, says Jakob Haardt, Senior Research & Innovation Manager and Head of the EURICE Berlin Office.
The project officially started on the 1st June 2022 and will run for a duration of four years. Funded through the European Union’s Horizon Europe Research and Innovation Programme, the project will receive EUR 5.9 million over the next four years. Additionally, the Swiss government will contribute EUR 1.8 million in funding for the Swiss Associated Partners. MELISSA will be coordinated by Maastricht University and will work closely on managing the project with Debiotech, the University of Bern and Eurice.
To find out more, please visit the project website under www.melissa-diabetes.eu.